EUVIMEDEUVIMED entdecken
Crossref

Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity

Jeries Kort, Nikolas Naleid, Frank Oley, James Ignatz-Hoover, Seunghee Margevicius, Pingfu Fu, Ehsan Malek, Brenda Cooper

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.02.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Jeries Kort und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Rese…. Hauptthemen laut MEDLINE: Melphalan, Multiple Myeloma, Neoplasm, Residual, Antineoplastic Agents, Alkylating. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelphalanMultiple MyelomaNeoplasm, ResidualAntineoplastic Agents, AlkylatingHumansFemaleMaleAgedRetrospective StudiesMiddle AgedHematopoietic Stem Cell TransplantationTreatment OutcomeTransplantation, AutologousFrail ElderlyAged, 80 and over

Stichwörter der Autor:innen

Autologous stem cell transplantationGeriatricsPersonalized medicinePharmacokineticsPlasma cell disorders

Substanzen

MelphalanAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Department of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH. Electronic address: jerieskort@gmail.co…
  • Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH.
  • Department of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH.
  • Department of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH.
  • Case Western Reserve University, Department of Population and Quantitative Health Sciences, Cleveland, OH.

Zitieren

APA

Kort, J., Naleid, N., Oley, F., Ignatz-Hoover, J., Margevicius, S., Fu, P., Malek, E., & Cooper, B. (2025). Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.02.004

Vancouver

Kort J, Naleid N, Oley F, Ignatz-Hoover J, Margevicius S, Fu P, et al. Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.02.004

BibTeX
@article{Kort2025,
  author = {Kort, Jeries and Naleid, Nikolas and Oley, Frank and Ignatz-Hoover, James and Margevicius, Seunghee and Fu, Pingfu and Malek, Ehsan and Cooper, Brenda},
  title = {Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.02.004}
}
Kostenlos starten →